文献速递糖尿病肥胖与代谢综合征

替尔泊肽早期诱导胰岛素增敏:一项在肥胖合并2型糖尿病日本人群中开展的前瞻性、单臂、开放标签研究

Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.
PubMed 文献 · Diabetologia · 2025-07-22

该前瞻性、单臂、开放标签、单中心研究在肥胖合并2型糖尿病的日本人群中,采用高胰岛素-正常血糖钳夹技术评估替尔泊肽5 mg治疗12周对胰岛素敏感性的影响。16例完成研究,葡萄糖输注率从3.21升至5.16 mg min-1 kg-1(p<0.001),HbA1c从63.4降至43.6 mmol/mol(7.95%降至6.14%,p<0.001),体重下降4.9 kg(5.0%,p<0.001)。作者认为替尔泊肽在12周内显著改善胰岛素敏感性,提示早期代谢效应并非仅由体重下降所致。

要点

  • 替尔泊肽5 mg治疗12周使葡萄糖输注率从3.21升至5.16 mg min-1 kg-1(p<0.001)。
  • HbA1c从63.4降至43.6 mmol/mol(7.95%降至6.14%,p<0.001),体重下降4.9 kg(5.0%,p<0.001)。
  • 胰高血糖素从28.8 pg/ml显著降至20.8 pg/ml,但葡萄糖输注率变化与其他临床变量无显著关系。

核心结论

  • 替尔泊肽在12周内显著改善胰岛素敏感性,提示早期代谢效应并非仅由体重下降所致。

研究设计与样本

  • 前瞻性、单臂、开放标签、单中心研究,纳入肥胖合并2型糖尿病个体,替尔泊肽2.5 mg每周一次共4周后增至5 mg共8周,16例完成研究。

主要发现

  • 葡萄糖输注率从3.21升至5.16 mg min-1 kg-1(p<0.001)。
  • HbA1c从63.4降至43.6 mmol/mol(7.95%降至6.14%,p<0.001),体重下降4.9 kg(5.0%,p<0.001)。
  • 肌肉量、脂肪量和脂肪百分比分别显著下降1.8%、9.1%和4.5%。
  • 胰高血糖素从28.8 pg/ml显著降至20.8 pg/ml。
  • 简单线性回归分析显示葡萄糖输注率变化与其他临床变量之间无显著关系。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: This study investigated insulin sensitivity using the hyperinsulinaemic-euglycaemic clamp technique in individuals with obesity and type 2 diabetes treated with tirzepatide at the low dose of 5 mg over a 12-week treatment period. METHODS: This prospective, single-arm, open-label, single-centre study was conducted in obese individuals with type 2 diabetes. Participants received tirzepatide 2.5 mg once weekly for 4 weeks; the dose was then increased to 5 mg for the remaining 8 weeks. The primary outcome was change in the glucose infusion rate. Secondary outcomes were changes in HbA1c, body weight, body composition, lipid profile, glucagon level, the HOMA2-IR and HOMA2-%β indices, and the association of these variables with the glucose infusion rate (GIR). RESULTS: Sixteen participants completed the study. The GIR increased from 3.21 to 5.16 mg min-1 kg-1 (p<0.001). HbA1c decreased from 63.4 to 43.6 mmol/mol (7.95% to 6.14%, p<0.001) and body weight decreased by 4.9 kg (5.0%, p<0.001). Muscle mass, fat mass and fat percentage significantly decreased by 1.8%, 9.1% and 4.5%, respectively. Glucagon decreased significantly from 28.8 pg/ml to 20.8 pg/ml. However, simple linear regression analysis revealed no significant relationship between changes in GIR and other clinical variables. CONCLUSIONS/INTERPRETATION: Tirzepatide significantly improves insulin sensitivity within 12 weeks, indicating an early metabolic effect that is not solely attributable to weight loss. TRIAL REGISTRATION: UMIN registration number: UMIN000056862.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Yamaguchi Y, Kuwata H, Imura M, et al. Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes. Diabetologia. 2025. PMID: 40694059. doi:10.1007/s00125-025-06493-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。